Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYKZB3)

• Drug Name: Anti-DR5 cells Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hepatocellular carcinoma	2C12.02	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMYKZB3

Molecule-Related Drug Atlas

Drug(s) Targeting TRAIL receptor 2 (TRAIL-R2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[2]
Lexatumumab	DMOS5JZ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
IGM-8444	DMFJXDZ	Hematologic tumour	2B33.Y	Phase 1	[4]
INBRX-109	DMUNSPI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
BI 905711	DME9NYV	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
DS-8273	DMJPUDW	Colorectal cancer	2B91.Z	Phase 1	[7]
GEN1029	DMV8IWJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
RhApo2L/TRAIL	DMIAZJ9	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1/2	[2]
LBY-135	DMSRD5U	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[9]
HGS-TR2J	DM0W2TA	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TRAIL receptor 2 (TRAIL-R2)	TTW20TU	TR10B_HUMAN	CAR-T-Cell-Therapy	[1]

References

• [1] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [2] Clinical pipeline report, company report or official report of Amgen (2009).
• [3] National Cancer Institute Drug Dictionary (drug id 528015).
• [4] Clinical pipeline report, company report or official report of IGM Biosciences.
• [5] Clinical pipeline report, company report or official report of Inhibrx.
• [6] Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Mol Cancer Ther. 2021 Jan;20(1):96-108.
• [7] First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):298-306.
• [8] National Cancer Institute Drug Dictionary (drug name Tilogotamab).
• [9] Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2014 Feb;32(1):135-44.
• [10] Enhancement of Glioma Radiation Therapy and Chemotherapy Response with Targeted Antibody Therapy Against Death Receptor 5. Int J Radiat Oncol Biol Phys. 2008 June 1; 71(2): 507-516.